Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and the best dose of trebananib and temsirolimus
when given together in treating patients with solid tumors that are metastatic or cannot be
removed by surgery. Trebananib may stop the growth of tumor cells by blocking blood flow to
the tumor. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes
needed for cell growth. Giving trebananib with temsirolimus may be an effective treatment for
solid tumors.